|
|
|
| Comparison of somatic gene mutation between 114 cases with different subtypes of thyroid papillary carcinoma and the TCGA database |
| CAO Xingyue1, FANG Haisheng2, LI Xiao2, SHEN Meiping2, WU Xiaohong1
|
1. Department of Endocrinology, Geriatric Medicine Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China;
2. The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China |
|
|
|
|
Abstract Objective To compare the difference in somatic gene mutation of PTC subtypes between 114 patients with papillary thyroid carcinoma (PTC) and The Cancer Genome Atlas (TCGA) database. Methods Totally 114 PTC patients admitted to The First Affiliated Hospital of Nanjing Medical University were recruited. The 18 hotspot genes associated with thyroid cancer were detected in thyroidectomy specimens were using next generation sequencing. PTC data were downloaded from the TCGA database in the cBioPortal website, and the difference in the somatic gene mutation was compared between 114 PTC patients and the TCGA database. Results The 114 PTC patients included 73 women (64.04%) and had a mean age of (39.23±13.18) years. The prevalence of BRAF V600E (66.67% vs. 48.68%), TERTp (3.51% vs. 0.41%), PDGFRA (1.75% vs. 0%), PTEN (3.51% vs. 0.41%) and TP53 gene mutations (4.39% vs. 0.61%) was significantly higher among the 114 PCT patients than in the TCGA database (P<0.05). The prevalence of BRAF V600E (80.88% vs. 54.99%), TP53 (7.35% vs. 0.57%) and TSHR gene mutations (2.94% vs. 0%) was significantly higher in classical PTC(CPTC) patients than in the TCGA database, and the prevalence of BRAF V600E (36.84% vs.13.86%) and TERTp gene mutations (10.53% vs. 0%) was significantly higher in follicular variant PTC (FVPTC) patients than in the TCGA database. According to the American Thyroid Association Risk Stratification of Thyroid Cancer Recurrence, the prevalence of BRAF V600E and TP53 gene mutations was 77.14% and 8.57% among moderate-risk CPTC patients, the prevalence of BRAF V600E gene mutation was 27.27% among low-risk FVPTC patients, and the prevalence of TERTp gene mutation was 33.33% among moderate-risk FVPTC patients, which were all higher than in the TCGA database (55.10%, 0%, 3.28%, and 0%, respectively; P<0.05). Conclusion There are significant differences in the type and rate of somatic gene mutations between 114 PTC patients and the TCGA database.
|
|
Received: 10 November 2022
Revised: 03 January 2023
Published: 21 February 2023
|
|
|
|
|
|
[1] ABDULLAH M I,JUNIT S M,NG K L,et al.Papillary thyroid cancer:genetic alterations and molecular biomarker investigations[J].Int J Med Sci,2019,16(3):450-460.
[2] KAKUDO K,BYCHKOV A,BAI Y,et al.The new 4th edition World Health Organization classification for thyroid tumors,Asian perspectives[J].Pathol Int,2018,68(12):641-664.
[3] 张萌,段焕利,王雷明,等.高侵袭性甲状腺乳头状癌的临床病理及分子特征分析[J].中华病理学杂志,2021,50(11):1234-1239.
[4] KIM T H,LEE M,KWON A Y,et al.Molecular genotyping of the non-invasive encapsulated follicular variant of papillary thyroid carcinoma[J].Histopathology,2018,72(4):648-661.
[5] COCA-PELAZ A,SHAH J P,HERNANDEZ-PRERA J C,et al.Papillary thyroid cancer-aggressive variants and impact on management:a narrative review[J].Adv Ther,2020,37(7):3112-3128.
[6] SONG Y S,LIM J A,PARK Y J.Mutation profile of well-differentiated thyroid cancer in Asians[J].Endocrinol Metab,2015,30(3):252-262.
[7] TUTTLE R M,HAUGEN B,PERRIER N D.Updated American Joint Committee on Cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer(eighth edition):what changed and why?[J].Thyroid,2017,27(6):751-756.
[8] HAUGEN B R,ALEXANDER E K,BIBLE K C,et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133.
[9] HONG A R,LIM J A,KIM T H,et al.The frequency and clinical implications of the BRAF(V600E) mutation in papillary thyroid cancer patients in Korea over the past two decades[J].Endocrinol Metab,2014,29(4):505-513.
[10] JUNG C K,LITTLE M P,LUBIN J H,et al.The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations[J].J Clin Endocrinol Metab,2014,99(2):E276-E285.
[11] 魏洪发,宁洁,冯小玲.甲状腺乳头状癌分子生物学标志物的研究进展[J].医学综述,2018,24(21):4208-4213.
[12] HAROON A L,RASHEED M R,XU B.Molecular alterations in thyroid carcinoma[J].Surg Pathol Clin,2019,12(4):921-930.
[13] 李文华,韩春.RET/PTC重排与甲状腺乳头状癌的关系研究[J].国际耳鼻咽喉头颈外科杂志,2022,46(5):296-299,304.
[14] VALVO V,NUCERA C.Coding molecular determinants of thyroid cancer development and progression[J].Endocrinol Metab Clin North Am,2019,48(1):37-59.
[15] SOLOMON J P,BENAYED R,HECHTMAN J F,et al.Identifying patients with NTRK fusion cancer[J].Ann Oncol,2019,30(Suppl.8):Ⅷ16-Ⅷ22.
[16] KELLY L M,BARILA G,LIU P,et al.Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer[J].Proc Natl Acad Sci U S A,2014,111(11):4233-4238.
[17] LIANG J,CAI W,FENG D,et al.Genetic landscape of papillary thyroid carcinoma in the Chinese population[J].J Pathol,2018,244(2):215-226. |
|
|
|
